Explore the words cloud of the ADAPT-SMART project. It provides you a very rough idea of what is the project "ADAPT-SMART" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||4˙064˙146 €|
|EC max contribution||1˙130˙000 € (28%)|
1. H2020-EU.220.127.116.11. (Other)
|Duration (year-month-day)||from 2015-07-01 to 2018-04-30|
Take a look of project's partnership.
|1||STICHTING LYGATURE||NL (UTRECHT)||coordinator||522˙000.00|
|2||NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE||UK (MANCHESTER)||participant||232˙500.00|
|3||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||135˙500.00|
|4||EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION||FR (Paris)||participant||78˙000.00|
|5||FORUM EUROPEEN DES PATIENTS (FPE)||LU (LUXEMBOURG)||participant||78˙000.00|
|6||AGENZIA ITALIANA DEL FARMACO||IT (ROMA)||participant||28˙000.00|
|7||HAUTE AUTORITE DE SANTE||FR (SAINT DENIS LA PLAINE CEDEX)||participant||28˙000.00|
|8||ZORGINSTITUUT NEDERLAND||NL (DIEMEN)||participant||28˙000.00|
|9||AbbVie Ltd||UK (Maidenhead)||participant||0.00|
|11||ASTELLAS PHARMA EUROPE LTD||UK (CHERTSEY)||participant||0.00|
|12||ASTRAZENECA AB||SE (SODERTAELJE)||participant||0.00|
|13||Bayer Pharma AG||DE (Berlin)||participant||0.00|
|14||BOEHRINGER INGELHEIM INTERNATIONALGMBH||DE (INGELHEIM)||participant||0.00|
|15||BRISTOL-MYERS SQUIBB COMPANY CORP||US (NEW YORK)||participant||0.00|
|16||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|17||F. HOFFMANN-LA ROCHE AG||CH (BASEL)||participant||0.00|
|18||FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES||BE (BRUXELLES)||participant||0.00|
|19||GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.||UK (BRENTFORD)||participant||0.00|
|20||H. LUNDBECK AS||DK (VALBY)||participant||0.00|
|21||INSTITUT DE RECHERCHES INTERNATIONALES SERVIER||FR (SURESNES)||participant||0.00|
|22||IPSEN INNOVATION SAS||FR (LES ULIS)||participant||0.00|
|23||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|24||LYSOGENE||FR (NEUILLY SUR SEINE)||participant||0.00|
|25||MASSACHUSETTS INSTITUTE OF TECHNOLOGY||US (CAMBRIDGE)||participant||0.00|
|26||MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN||DE (DARMSTADT)||participant||0.00|
|27||MERCK SHARP & DOHME CORP||US (WHITEHOUSE STATION NJ)||participant||0.00|
|28||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|29||NOVO NORDISK A/S||DK (BAGSVAERD)||participant||0.00|
|30||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|31||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
|32||SHIRE INTERNATIONAL GMBH||CH (ZUG)||participant||0.00|
|34||THE EUROPEAN MEDICINES AGENCY||UK (LONDON)||participant||0.00|
|35||UCB BIOPHARMA SRL||BE (BRUXELLES)||participant||0.00|
Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major adaptations to current paradigms of bringing medicines to patients are required in order to realize that potential and to address important challenges in the healthcare ecosystem. Against this background, several initiatives are exploring new pathways to market, collectively referred to as Medicines Adaptive Pathways to Patients (MAPPs). The ADAPT-SMART consortium is aligning a limited number of major stakeholders eager to progress towards MAPPs implementation. It will act as a neutral collaborative platform that will engage industry, SMEs, regulators, Health Technology Assessment bodies (HTAs), payers, governments, clinicians and patients. The ADAPT-SMART consortium will contribute to align understanding of the impact of MAPPs, to share learnings between all stakeholders, and to allow the field to actively work towards MAPPs implementation. The impact of the ADAPT-SMART CSA will be a result of the delivery of • actionable advice/recommendations to IMI on how to best leverage results from past/current projects; • concrete proposals for future (IMI) projects; • actionable advice/recommendations and information to other actors in the healthcare environment; • synthesis of learnings from pilot projects and case studies with relevance to MAPPs; • communication of CSA outcomes by way of publications and conference presentations. This CSA will increase the probability of successful implementation of MAPPs and accelerate access to crucial therapies, thus improving the position of both the patients in need of novel treatments and the research-based pharmaceutical industry.
|Identification of legal constraints for MAPPs||Documents, reports||2019-10-08 14:17:21|
|Short report-horizon scanning of future IMI and non-IMI projects with release of a summary of the findings||Documents, reports||2019-10-08 14:17:59|
|Operational portal to allow for internal team information||Other||2019-10-08 14:17:41|
|Map of the different transition/engagement moments with stakeholders, and identify the information and data needs of these stakeholders at each of these moments||Documents, reports||2019-10-08 14:17:15|
|Update D1.02 â€“ Document- analysis of already completed IMI and non-IMI projects and their outputs||Documents, reports||2019-10-08 14:18:05|
|Recommendations on applicability of managed entry agreements and pricing arrangements to possible adaptive scenarios||Documents, reports||2019-10-08 14:17:39|
|Matrix that contrasts decision points in current vs. future processes by stakeholder groups and implications for a roadmap for implementation. (workshop in M7)||Documents, reports||2019-10-08 14:17:17|
|Document-analysis of already completed IMI and non-IMI projects and their outputs||Documents, reports||2019-10-08 14:17:45|
|Briefing documents during project about EMA pilots to relevant leads of the working groups in the project||Documents, reports||2019-10-08 14:17:16|
|Create ADAPT SMART infographic||Other||2019-10-08 14:17:48|
|Detailed work plan for each deliverable including staffing 1||Documents, reports||2019-10-08 14:17:40|
|Organisation of closing event||Other||2019-10-08 14:18:03|
|Inventory and analysis of increased uncertainties for patients and other stakeholders and the issues these raise||Documents, reports||2019-10-08 14:17:37|
|Proposal for pragmatic operational criteria for the respective decision(s) to use the MAPPs pathway, the timing and the stakeholders needed for this decision. (workshop in M6, briefing document M4)||Documents, reports||2019-10-08 14:18:07|
|Detailed work plan for each deliverable including staffing 3||Documents, reports||2019-10-08 14:17:20|
|List of relevant stakeholders (and updated)||Other||2019-10-08 14:17:42|
|Inventory/Paper on the available managed entry agreements, including pricing models and their experiences as judged by the different stakeholders||Documents, reports||2019-10-08 14:17:42|
|Glossary with agreed operational definitions of the terms used in international literature||Documents, reports||2019-10-08 14:18:08|
|Report with recommendations on current tools and systems to guide the appropriate use by the targeted patient groups, both at the European and national level (also input for D3.09). (workshop in M16)||Documents, reports||2019-10-08 14:17:15|
|Review/paper on the ethical and legal aspects of prescribing and use by target populations||Documents, reports||2019-10-08 14:17:40|
|Collaborative research proposals based on gap analysis||Documents, reports||2019-10-08 14:18:08|
|Gap analysis and where appropriate recommendations for projects addressing enablers of decision making in an adaptive environment (e.g. managing uncertainties at HTA level). (interim: M6, M18)||Documents, reports||2019-10-08 14:17:20|
|Position paper on the impact of adaptive licencing and adaptive access on IP and regulatory data protection periods and recommendations||Documents, reports||2019-10-08 14:17:39|
|Project templates and materials for communication||Other||2019-10-08 14:17:42|
|Six-monthly reports on project progress and completion (first in M6, then every 6 months)||Documents, reports||2019-10-08 14:17:43|
|Points to consider document on ethical and legal aspects of adaptive decision-making and recommendations on how these can be addressed||Documents, reports||2019-10-08 14:17:43|
|Project meetings scheduled and organized||Other||2019-10-08 14:17:46|
|Management of IP||Other||2019-10-08 14:17:45|
|Detailed work plan for each deliverable including staffing 2||Documents, reports||2019-10-08 14:18:06|
|Press releases (various releases during project)||Other||2019-10-08 14:17:48|
|Project website||Websites, patent fillings, videos etc.||2019-10-08 14:17:42|
|Select methods, toolset (such as the Janus program) and datasets to perform scenario studies in order to facilitate stakeholderâ€™s engagement||Documents, reports||2019-10-08 14:18:08|
|Reports to IMI (first in M18, then M30)||Documents, reports||2019-10-08 14:17:45|
|Detailed project plans/tools for use by the consortium||Documents, reports||2019-10-08 14:17:41|
|External communications plan (and updated)||Documents, reports||2019-10-08 14:17:42|
Take a look to the deliverables list in detail: detailed list of ADAPT-SMART deliverables.
|year||authors and title||journal||last update|
Hans-Georg Eichler, Richard Barker, Nicola Bedlington, Jacoline C. Bouvy, AndrÃ© W. Broekmans, Anna Bucsics, Francesca Cerreta, Solange Corriol-Rohou, Alicia Granados, Yann Le Cam, Ad Schuurman
The evolution of adaptiveness: balancing speed and evidence
published pages: , ISSN: 1474-1776, DOI: 10.1038/nrd.2018.90
|Nature Reviews Drug Discovery||2019-05-16|
Patient Access in the Context of Adaptive Pathways for Medicines: What Could Make It Work?
published pages: 11-13, ISSN: , DOI:
|Value and Outcomes Spotlight||2019-05-15|
Hans-Georg Eichler, Nicola Bedlington, Mathieu Boudes, Jacoline C. Bouvy, AndrÃ© W. Broekmans, Francesca Cerreta, Stuart D. Faulkner, Sue Forda, Angelika Joos, Yann Le Cam, Mark Mayer, Vinciane Pirard, Solange Corriol-Rohou
Medicines Adaptive Pathways to Patients: Why, when and how to engage?
published pages: , ISSN: 0009-9236, DOI: 10.1002/cpt.1121
|Clinical Pharmacology & Therapeutics||2019-05-15|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADAPT-SMART" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ADAPT-SMART" are provided by the European Opendata Portal: CORDIS opendata.
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854Read More
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842Read More
Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890Read More